Sera Prognostics (NASDAQ:SERA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Sera Prognostics (NASDAQ:SERA) posted its earnings results on Wednesday. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01, FiscalAI reports. Sera Prognostics had a negative net margin of 39,417.29% and a negative return on equity of 36.12%. The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.03 million.

Here are the key takeaways from Sera Prognostics’ conference call:

• PRIME publication reported in January 2026 showed large clinical benefits — including a 56% fewer births before 32 weeks, 32% fewer before 35 weeks, and ~20% reduction in NICU admissions — providing RCT-level evidence the company will use to drive adoption and payer discussions.
• Commercial traction accelerated in 2025 with engagement expanding to 13 states, active discussions with ~10 payers, two live partner programs, and a target of 15–17 states and 5–7 partner programs by year-end 2026 to generate outcomes and economic data.
• The company is pursuing a European market entry, working toward CE marking with dossiers planned in the coming months and supportive expert commentary, but regulatory approval and commercialization timing remain uncertain.
• Revenue remains immaterial (FY2025 revenue ~$81,000, Q4 revenue $10,000) and the company reported a FY2025 net loss of ~$31.9M, underscoring early-stage commercial risk and continued reliance on evidence/coverage milestones to drive meaningful revenue.
• Sera ended 2025 with ~$95.8M in cash and securities, expects runway into 2028, is reallocating spend from R&D to commercial activities, and reestablished an ATM for optionality while stating no immediate plans to issue shares.

Sera Prognostics Stock Down 6.3%

Sera Prognostics stock opened at $1.79 on Friday. The stock has a market cap of $69.09 million, a price-to-earnings ratio of -2.63 and a beta of 1.01. Sera Prognostics has a 12-month low of $1.37 and a 12-month high of $4.20. The business’s 50-day simple moving average is $2.64 and its 200 day simple moving average is $3.01.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SERA. Weiss Ratings reissued a “sell (d-)” rating on shares of Sera Prognostics in a report on Monday, December 29th. Jefferies Financial Group raised Sera Prognostics to a “strong-buy” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Insider Transactions at Sera Prognostics

In other Sera Prognostics news, CEO Zhenya Lindgardt sold 22,639 shares of Sera Prognostics stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $1.90, for a total transaction of $43,014.10. Following the completion of the sale, the chief executive officer owned 741,287 shares of the company’s stock, valued at approximately $1,408,445.30. The trade was a 2.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 57,133 shares of company stock valued at $115,794 over the last quarter. 13.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Sera Prognostics

Several institutional investors have recently modified their holdings of SERA. Lido Advisors LLC acquired a new position in Sera Prognostics during the third quarter valued at approximately $68,000. Cetera Investment Advisers bought a new position in shares of Sera Prognostics during the fourth quarter worth $74,000. Two Sigma Investments LP bought a new position in shares of Sera Prognostics during the third quarter worth $97,000. Qube Research & Technologies Ltd acquired a new position in shares of Sera Prognostics in the 2nd quarter valued at $92,000. Finally, Barclays PLC grew its holdings in shares of Sera Prognostics by 267.4% in the 4th quarter. Barclays PLC now owns 36,722 shares of the company’s stock valued at $108,000 after buying an additional 26,726 shares during the period. 54.64% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Sera Prognostics

Here are the key news stories impacting Sera Prognostics this week:

• Positive Sentiment: PRIME study publication strengthens clinical case for PreTRM®: Sera highlighted the PRIME randomized trial (5,018 women) showing PreTRM reduced earliest preterm births and newborn complications — a major data milestone that supports future commercial adoption. SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
• Positive Sentiment: Clear commercial expansion plan and funded runway: Management outlined a plan to expand partner programs to 15–17 states by year‑end 2026 and said cash runway extends through 2028, lowering near‑term financing risk if execution stays on track. Sera Prognostics outlines plan to expand partner programs to 15–17 states
• Neutral Sentiment: EPS slightly better than expected but still a loss: SERA reported Q4 EPS of ($0.16) vs. consensus ($0.17) — a small beat that reduces some near‑term earnings concern but does not change the company’s path to profitability. Sera Prognostics Q4 2025 Earnings Call Transcript
• Negative Sentiment: Revenue materially missed estimates and the call emphasized “revenue‑light”: Q4 revenue was essentially negligible (~$0.01M) versus consensus ~ $0.03M, reinforcing concerns that commercial uptake and near‑term sales remain limited. Analysts and investors are focused on when meaningful revenue growth will follow the clinical data. Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: Weak financial profile and technicals pressure the stock: Sera still posts very large negative margins and negative ROE; the share price sits below its 50‑ and 200‑day moving averages and traders are de‑risking into the print. Sera Prognostics (SERA) Stock Profile

About Sera Prognostics

Sera Prognostics, Inc is a precision medicine company focused on improving pregnancy outcomes through proteomic testing. The company’s flagship product, the PreTRM™ test, is a blood-based assay designed to assess a woman’s risk of delivering prematurely by measuring specific protein biomarkers in maternal serum. By identifying patients at elevated risk for spontaneous preterm birth, Sera Prognostics aims to enable earlier interventions and tailored care plans that can reduce the incidence of neonatal complications associated with early delivery.

Since its founding in 2014 and subsequent initial public offering in 2020, Sera Prognostics has worked closely with clinical research networks and obstetric care providers across the United States to validate the clinical performance of its PreTRM test.